Hot or Not, Stock Market Edition: 07/30/2026

Happy Thursday, everyone. Here’s what’s hot and what’s not today in the Zen Ratings: 

• Hot: Mental health provider LifeStance Health (LFST) is riding healthcare's most durable demand wave; pharma titan Eli Lilly (LLY) proves giants can still sprint
• Not: Lunar lander maker Intuitive Machines (LUNR) is learning gravity applies to stocks too; airline operator Alaska Air (ALK) is flying last in its class

P.S. For more stocks making moves, check out our Zen Ratings Upgrades & Downgrades screener.

A note from our sponsors...

10 Stocks for Income and Triple-Digit Potential

If you're looking for income, stability, and upside, this is the list you want. Our Top 10 Best Stocks to Own in the Second Half of 2026 features elite dividend growers - companies that have historically boosted payouts while delivering market-beating gains. In the right market environment, these stocks can double, triple, even quintuple your annual dividend income over time. Combine that with post rate cut upside potential and you've got a rare opportunity for compounding gains on two fronts.

This report is free for a limited time - download it now before it disappears behind the paywall.

🔥 HOT: Mental health services provider LifeStance Health (LFST) is riding one of healthcare's most durable demand shifts. Outpatient mental health care has moved firmly into the mainstream — insurers now cover it broadly, and employers treat behavioral health as a core benefit rather than a nice-to-have. LifeStance was built for precisely this moment, with thousands of clinicians providing in-person and virtual therapy billed through insurance instead of paid out of pocket. Investors have begun pricing that in: the stock ran from around $8 in mid-May to above $10 by late June, a climb of more than 25% in roughly six weeks. 

The ratings describe an elite growth profile. LFST holds a B Zen Rating (Buy) and ranks #5 of 43 in Medical Care Facilities, an A grade industry. Its two standout scores tell the story: an A for Growth in the top 1% and an A for Sentiment in the top 2%, a pairing that points to rapid business expansion with smart money moving in behind it. A secular demand wave, a top-five industry rank, and grades that high put LifeStance among the most compelling growth stories in healthcare today. 

🥶 NOT: Lunar lander maker Intuitive Machines (LUNR) is learning that gravity applies to share prices as well. The stock has fallen from roughly $40 in early June to under $12 yesterday, shedding around 70% in about six weeks — and the people who know the company best sold the entire way down. Co-founder and director Kamal Ghaffarian executed at least six separate sales worth millions between June and July, while the chief technology officer offloaded over $3 million in a single June session. A decline that steep paired with insider selling that persistently signals the market repricing the underlying story, not just the stock. 

The ratings had already flagged trouble before the slide steepened. LUNR carries a D Zen Rating (Sell), ranking #67 of 85 in the Defense industry, with an F for Sentiment — about as complete a smart-money exit as the scale can register — alongside an F for Financials and D grades in Value, Safety, and AI. Its only real strength, a B for Growth, confirms revenue is still expanding, but a topline alone can't support a valuation when nearly every other measure sits in failing territory. Space milestones make for great headlines; this one is better watched from the ground. 

🔥 HOT: Pharma titan Eli Lilly (LLY) is showing that scale and speed aren't mutually exclusive. Its GLP-1 franchise — the weight-loss and diabetes drugs sitting at the center of medicine's largest commercial opportunity — still faces demand it can't fully supply, and the stock has followed suit, rising more than 15% in a little over two months from under $1,000 in mid-May to about $1,150 by late July. What makes that unusual is Lilly's size: mega-caps rarely sustain price trends like this, and Lilly is managing it while a long line of would-be competitors, several of which have appeared on the NOT side of this newsletter, burn cash chasing a market it already dominates. 

The ratings capture that unusual combination. LLY earns a B Zen Rating (Buy) and ranks #7 of 16 in the A-rated General Drug Manufacturers industry. Momentum comes in at a B, remarkable for a company of this heft, paired with B grades in Value and Financials — evidence that the trend is strong while the price remains sensible against Lilly's earnings power. Wall Street agrees. 17 out 18 analysts covering LLY recommend rates either strong buy or buy. A dominant franchise, rare mega-cap momentum, and a top-tier industry make Lilly the anchor of today's HOT list. 

🥶 NOT: Airline operator Alaska Air Group (ALK) holds a title no carrier wants: last place, #18 of 18, inside an Airline industry that grades a healthy B. The contrast with the sector's leaders couldn't be starker, landing the same week we highlighted LATAM Airlines at #1 with unanimous analyst backing — the distance between the industry's best and worst has rarely been this easy to see. Alaska carries the weakest overall rating of any stock in today's lineup, weighed down by a D for Growth that ranks near the bottom of the entire market. While its peers capitalize on the travel-demand recovery, Alaska's earnings trajectory trails the whole field. 

The ratings show weakness with nothing to offset it. ALK carries a D Zen Rating (Sell) built on that D for Growth and C grades everywhere else, meaning not one component rises above average and there's no pillar to anchor a turnaround. In an industry where the strongest names are collecting unanimous Strong Buys, Alaska is the one the ratings say to skip until its growth stops lagging the pack. 

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.